Page 109 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Molecular docking against SARS-CoV-2

(2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. statistics software package for education and data analysis.
Paleontol Electron. 2001;4(1):9.
doi: 10.1038/s41422-020-0282-0
22. Zafari ZF, Sarmast SM. Estradiol and COVID-19: Does
11. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for
5 or 10 Days in patients with severe covid-19. N Engl J Med. 17-estradiol have an immune-protective function in
2020;383(19):1827-1837. women against coronavirus? J Family Reprod Health.
2021;15(3):150-159.
doi: 10.1056/NEJMoa2015301
doi: 10.18502/jfrh.v15i3.7132
12. López-Medina E, López P, Hurtado IC, et al. Effect of
ivermectin on time to resolution of symptoms among adults 23. Piplani S, Singh P, Petrovsky N, Winkler DA. Identifying
with mild COVID-19: A Randomized clinical trial. JAMA. SARS-CoV-2 drugs binding to the spike fatty acid binding
2021;325(14):1426-1435. pocket using in silico docking and molecular dynamics. Int J
Mol Sci. 2023;24(4):4192.
doi: 10.1001/jama.2021.3071
doi: 10.3390/ijms24044192
13. Pirolli D, Righino B, Camponeschi C, Ria F, Di Sante G,
De Rosa MC. Virtual screening and molecular dynamics 24. Gupta Y, Savytskyi OV, Coban M, et al. Protein structure-
simulations provide insight into repurposing drugs against based in-silico approaches to drug discovery: Guide to
SARS-CoV-2 variants Spike protein/ACE2 interface. Sci COVID-19 therapeutics. Mol Aspects Med. 2023;91:101151.
Rep. 2023;13:1494. doi: 10.1016/j.mam.2022.101151
doi: 10.1038/s41598-023-28716-8 25. Yang C, Pan X, Huang Y, et al. Drug repurposing of
itraconazole and estradiol benzoate against COVID-19 by
14. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies blocking SARS-CoV-2 spike protein-mediated membrane
and antiviral drugs against Omicron BA.2.12.1, BA.4, and fusion. Adv Ther (Weinh). 2021;4(5):2000224.
BA.5 subvariants. N Engl J Med. 2022;387(5):468-470.
doi: 10.1002/ADTP.202000224
doi: 10.1056/NEJMc2207519
26. Tsegay KB, Adetemi CM, Gniffke EP, Sather DN, Walker JK,
15. Wrapp D, Wang N, Corbett KS, et al. Prefusion 2019-nCoV
spike glycoprotein with a single receptor-binding domain Smith SEP. A repurposed drug screen identifies compounds
that inhibit the binding of the COVID-19 spike protein to
up. Science. 2020;367(6483):1260-1263.
ACE2. Front Pharmacol. 2021;12:685308.
doi: 10.1126/science.abb2507
doi: 10.3389/fphar.2021.685308
16. Pettersen EF, Goddard TD, Huang CC, et al. UCSF 27. Liesenborghs L, Spriet I, Jockmans D, et al. Itraconazole
Chimera--a visualization system for exploratory research for COVID-19: Preclinical studies and a proof-of-concept
and analysis. J Comput Chem. 2004;25(13):1605-1612.
randomized clinical trial. EBioMedicine. 2021;66:103288.
doi: 10.1002/jcc.20084
doi: 10.1016/j.ebiom.2021.103288
17. Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: 28. Van Damme E, De Meyer S, Bojkova D, et al. In vitro
Homology modelling of protein structures and complexes. activity of itraconazole against SARS-CoV-2. J Med Virol.
Nucleic Acids Res. 2018;46:W296-W303.
2021;93(7):4454-4460.
doi: 10.1093/nar/gky427
doi: 10.1002/jmv.26917
18. Banerjee P, Eckert OA, Schrey AK, Preissner R. ProTox-II: 29. Guilck RM, Su Z, Flexner C, et al. Phase 2 study of the
A webserver for the prediction of toxicity of chemicals. safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-
Nucleic Acids Res. 2018;2:W257-W263.
1-infected, treatment-experienced patients: AIDS clinical
doi: 10.1093/nar/gky318 trials group 5211. J Infect Dis. 2007;196(2):304-312.
19. Burley SK, Bhikadiya C, Bi C, et al. RCSB Protein Data Bank doi: 10.1086/518797
(RCSB.org): Delivery of experimentally-determined PDB 30. Cuesta-Llavona E, Gómez J, Albaiceta GM, et al. Variant-
structures alongside one million computed structure models genetic and transcript-expression analysis showed a role for
of proteins from artificial intelligence/machine learning. the chemokine-receptor CCR5 in COVID-19 severity. Int
Nucleic Acids Res. 2023;51(6):D488-D508.
Immunopharmacol. 2021;98:107825.
doi: 10.1093/nar/gkac1077
doi: 10.1016/J.INTIMP.2021.107825
20. Dallakyan S, Olson AJ. Small-molecule library screening by 31. Risner KH, Tieu KV, Wang YG, et al. Maraviroc inhibits
docking with pyrx. Methods Mol Biol. 2015;1263:243-250.
SARS-CoV-2 multiplication and s-protein mediated cell
doi: 10.1007/978-1-4939-2269-7_19 fusion in cell culture. BioRxiv [Preprint]. 2020.
21. Hammer O, Harper DAT, Ryan PD. PAST: Paleontological doi: 10.1101/2020.08.12.246389

Volume 7 Issue 2 (2024) 6 doi: 10.36922/itps.1651